Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Clin Cancer Res. 2016 Jan 5;22(9):2250–2260. doi: 10.1158/1078-0432.CCR-15-2276

Figure 2. Pharmacokinetic analysis of GDC-0941.

Figure 2

A) Mice were treated with GDC-0941. Blood was collected at the indicated time points after drug administration, and plasma was used to measure GDC-0941 levels. B) Mice bearing MCF-7 tumors were pretreated with fulv, then treated 3 d later with GDC-0941. Tumors harvested at the indicated time points were used to measure GDC-0941 levels. An additional group of mice was treated with a second dose of GDC-0941 (100 mg/kg) at 12 h. Data are presented as mean of triplicates + SD.